



MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an Independent Licensee of the Blue Cross and Blue Shield Association

Medical Policy

Heart/Lung Transplant

Table of Contents

- [Policy: Commercial](#)
- [Policy: Medicare](#)
- [Authorization Information](#)
- [Coding Information](#)
- [Description](#)
- [Policy History](#)
- [Information Pertaining to All Policies](#)
- [References](#)

Policy Number: 269

BCBSA Reference Number: 7.03.08

NCD/LCD: N/A

Related Policies

Heart Transplant, #[197](#)

Lung and Lobar Lung Transplantation, #[015](#)

Policy

Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO BlueSM and Medicare PPO BlueSM Members

Heart-lung transplantation may be **MEDICALLY NECESSARY** for carefully selected patients with end-stage cardiac and pulmonary disease including, but not limited to, one of the following diagnoses:

- Irreversible primary pulmonary hypertension with heart failure or
- Non-specific severe pulmonary fibrosis or
- Eisenmenger complex with irreversible pulmonary hypertension and heart failure or
- Cystic fibrosis with severe heart failure or
- Chronic obstructive pulmonary disease with heart failure or
- Emphysema with severe heart failure, or
- Pulmonary fibrosis with uncontrollable pulmonary hypertension or heart failure.

Heart/lung retransplantation after a failed primary heart/lung transplant may be considered **MEDICALLY NECESSARY** in patients who meet criteria for heart/lung transplantation.

Heart/lung transplantation is considered **INVESTIGATIONAL** in all other situations.

In addition to the above information, we do not cover heart/lung transplantation when any of the following conditions are present:

- Known current malignancy, including metastatic cancer
- Recent malignancy with high risk of recurrence
 - Note: the assessment of risk of recurrence for a previously treated malignancy is made by the transplant team; providers must submit a statement with an explanation of why the patient with a recently treated malignancy is an appropriate candidate for a transplant.

- Untreated systemic infection making immunosuppression unsafe, including chronic infection
- Other irreversible end-stage disease not attributed to heart or lung disease
- History of cancer with a moderate risk of recurrence
- Systemic disease that could be exacerbated by immunosuppression
- Psychosocial conditions or chemical dependency affecting ability to adhere to therapy

Harvesting of the donor's organ is **MEDICALLY NECESSARY** when the donor is not a member, as long as the recipient is a member. Harvesting is defined to include the surgical removal of the donor's organ and related medically necessary services and/or tests that are required to perform the transplant itself.

Prior Authorization Information

Pre-service approval is required for all inpatient services for all products.

See below for situations where prior authorization may be required or may not be required for outpatient services.

Yes indicates that prior authorization is required.

No indicates that prior authorization is not required.

N/A indicates that this service is primarily performed in an inpatient setting.

	Outpatient
Commercial Managed Care (HMO and POS)	N/A
Commercial PPO and Indemnity	N/A
Medicare HMO BlueSM	N/A
Medicare PPO BlueSM	N/A

Medicare Managed Care and Medicare PPO members, who meet the coverage criteria for heart-lung transplantation, must be referred to a Medicare certified transplant facility.

Medicare Certified Transplant Facilities:

<http://www.cms.gov/Medicare/Provider-Enrollment-and-Certification/CertificationandCompliance/downloads/ApprovedTransplantPrograms.pdf>

CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

CPT Codes

CPT codes:	Code Description
33935	Heart-lung transplant with recipient cardiectomy-pneumonectomy

ICD-10 Procedure Codes

ICD-10-PCS procedure codes:	Code Description
0BYK0Z0	Transplantation of Right Lung, Allogeneic, Open Approach
02YA0Z0	Transplantation of Heart, Allogeneic, Open Approach
02YA0Z1	Transplantation of Heart, Syngeneic, Open Approach
0BYL0Z0	Transplantation of Left Lung, Allogeneic, Open Approach
0BYM0Z0	Transplantation of Bilateral Lungs, Allogeneic, Open Approach
0BYM0Z1	Transplantation of Bilateral Lungs, Syngeneic, Open Approach

Description

HEART/LUNG CANDIDATES REQUIRING TRANSPLANTATION

Most heart/lung transplant recipients have Eisenmenger syndrome (37%), followed by idiopathic pulmonary artery hypertension (28%) and cystic fibrosis (14%). Eisenmenger syndrome is a form of congenital heart disease in which systemic-to-pulmonary shunting leads to pulmonary vascular resistance. It is possible that pulmonary hypertension could lead to a reversal of the intracardiac shunting and inadequate peripheral oxygenation or cyanosis.

Treatment

Combined heart/lung transplantation is intended to prolong survival and improve function in patients with end-stage cardiac and pulmonary diseases. Due to corrective surgical techniques and improved medical management of pulmonary hypertension, the total number of patients with Eisenmenger syndrome has seen a decline in recent years. Additionally, heart/lung transplants have not increased appreciably, but for other indications, it has become more common to transplant a single or double lung and maximize medical therapy for heart failure, rather than perform a combined transplant. For those indications, patient survival rates following heart/lung transplantations are similar to lung transplant rates. Bronchiolitis obliterans syndrome is a major complication. One-, 5-, and 10-year patient survival rates for heart/lung transplants performed between 1982 and 2014 were estimated at 63%, 45%, and 32%, respectively.

In 2017, 29 individuals received heart/lung transplants in the United States. As of April 2018, 51 patients were on the waiting list for heart/lung transplants.

Summary

For individuals who have end-stage cardiac and pulmonary disease who receive combined heart/lung transplant, the evidence includes case series and registry data. Relevant outcomes are overall survival, symptoms, morbid events, and treatment-related morbidity and mortality. The available literature describes outcomes after heart/lung transplantation. Given the exceedingly poor expected survival rates without transplantation, this evidence is sufficient to demonstrate that heart/lung transplantation provides a survival benefit in appropriately selected patients. Transplant may be the only option for some patients with end-stage cardiopulmonary disease. Heart/lung transplant is contraindicated for patients in whom the procedure is expected to be futile due to comorbid disease or for whom posttransplantation care is expected to worsen comorbid conditions significantly. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have a combined heart/lung transplant complicated by graft failure or severe dysfunction of the heart/lung and who receive a combined heart/lung retransplant, the evidence includes case series and registry data. Relevant outcomes are overall survival, symptoms, morbid events, and treatment-related morbidity and mortality. A very limited amount of data has suggested that, after controlling for confounding variables, survival rates after primary and repeat heart/lung transplants are similar. Findings are not conclusive due to the small number of cases of repeat heart/lung transplants reported in the published literature. Repeat heart/lung transplantation is, however, likely to improve outcomes in patients with a prior failed transplant who meet the clinical criteria for heart/lung transplantation. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

Policy History

Date	Action
10/2018	BCBSA National medical policy review. No changes to policy statements. New references added. Background and summary clarified.
11/2017	New references added from BCBSA National medical policy.
1/2016	New references added from BCBSA National medical policy.
12/2014	New references added from BCBSA National medical policy.
10/2014	Medical policy remediation: New indications for non-coverage. Clarified coding information. Effective 10/1/2014.
6/2014	Updated Coding section with ICD10 procedure and diagnosis codes, effective 10/2015.
4/2014	BCBSA National medical policy review.

	New medically necessary and investigational indications described. Effective 4/1/2014.
11/2011-4/2012	Medical policy ICD 10 remediation: Formatting, editing and coding updates. No changes to policy statements.
10/2011	Reviewed - Medical Policy Group – Gastroenterology, Nutrition, and Organ Transplantation. No changes to policy statements.
3/22/2011	BCBSA National medical policy review. No changes to policy statement.
11/2010	Reviewed - Medical Policy Group – Gastroenterology, Nutrition, Organ Transplantation No changes to policy statements.
11/2009	Reviewed - Medical Policy Group – Gastroenterology, Nutrition, Organ Transplantation No changes to policy statements.
9/2009	BCBSA National medical policy review. No changes to policy statements.
11/2008	Reviewed - Medical Policy Group – Gastroenterology, Nutrition, Organ Transplantation No changes to policy statements.
8/2008	BCBSA National medical policy review. No changes to policy statements.
11/2007	Reviewed - Medical Policy Group – Gastroenterology, Nutrition, Organ Transplantation. No changes to policy statements.
11/2006	Reviewed - Medical Policy Group – Gastroenterology, Nutrition, Organ Transplantation. No changes to policy statements.

Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)

References

1. Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report--2010. *J Heart Lung Transplant*. Oct 2010;29(10):1104-1118. PMID 20870165
2. Yusen RD, Edwards LB, Dipchand AI, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Lung and Heart-Lung Transplant Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. *J Heart Lung Transplant*. Oct 2016;35(10):1170-1184. PMID 27772669
3. Organ Procurement and Transplantation Network (OPTN). View Data Reports. n.d.; <https://optn.transplant.hrsa.gov/data/view-data-reports/>. Accessed July 16, 2018.
4. Kalogeropoulos AP, Georgiopoulou VV, Giamouzis G, et al. Utility of the Seattle Heart Failure Model in patients with advanced heart failure. *J Am Coll Cardiol*. Jan 27 2009;53(4):334-342. PMID 19161882
5. United Network for Organ Sharing (UNOS). Heart/Lung: Submitting LAS exception requests for candidates diagnosed with PH. 2018; <https://transplantpro.org/news/thoracic/submitting-las-exception-requests-for-candidates-diagnosed-with-ph-2/>. Accessed July 16, 2018.
6. Organ Procurement and Transplantation Network (OPTN). Organ Procurement and Transplantation Network Policies. 2018; https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf. Accessed July 13, 2018.
7. Spahr JE, West SC. Heart-lung transplantation: pediatric indications and outcomes. *J Thorac Dis*. Aug 2014;6(8):1129-1137. PMID 25132980
8. Benden C, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: fifteenth pediatric lung and heart-lung transplantation report-2012. *J Heart Lung Transplant*. Oct 2012;31(10):1087-1095. PMID 22975098

9. Benden C, Goldfarb SB, Edwards LB, et al. The Registry of the International Society for Heart and Lung Transplantation: seventeenth official pediatric lung and heart-lung transplantation report--2014; focus theme: retransplantation. *J Heart Lung Transplant.* Oct 2014;33(10):1025-1033. PMID 25242126
10. Hill C, Maxwell B, Boulate D, et al. Heart-lung vs. double-lung transplantation for idiopathic pulmonary arterial hypertension. *Clin Transplant.* Dec 2015;29(12):1067-1075. PMID 26358537
11. Jayarajan SN, Taghavi S, Komaroff E, et al. Impact of extracorporeal membrane oxygenation or mechanical ventilation as bridge to combined heart-lung transplantation on short-term and long-term survival. *Transplantation.* Jan 15 2014;97(1):111-115. PMID 24056630
12. Goldfarb SB, Levvey BJ, Edwards LB, et al. The Registry of the International Society for Heart and Lung Transplantation: Nineteenth Pediatric Lung and Heart-Lung Transplantation Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. *J Heart Lung Transplant.* Oct 2016;35(10):1196-1205. PMID 27772671
13. Keeshan BC, Goldfarb SB, Lin KY, et al. Impact of congenital heart disease on outcomes of pediatric heart-lung transplantation. *Pediatr Transplant.* Mar 2014;18(2):204-210. PMID 24373099
14. Yusen RD, Edwards LB, Kucheryavaya AY, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-first adult lung and heart-lung transplant report--2014; focus theme: retransplantation. *J Heart Lung Transplant.* Oct 2014;33(10):1009-1024. PMID 25242125
15. Shuhaiber JH, Kim JB, Gibbons RD. Repeat heart-lung transplantation outcome in the United States. *J Heart Lung Transplant.* Oct 2008;27(10):1122-1127. PMID 18926404
16. Mistiaen WP. Heart transplantation in patients with previous malignancy. An overview. *Acta Cardiol.* Apr 2015;70(2):123-130. PMID 26148371
17. Oliveira GH, Hardaway BW, Kucheryavaya AY, et al. Characteristics and survival of patients with chemotherapy-induced cardiomyopathy undergoing heart transplantation. *J Heart Lung Transplant.* Aug 2012;31(8):805-810. PMID 22551930
18. Sigurdardottir V, Bjortuft O, Eiskjaer H, et al. Long-term follow-up of lung and heart transplant recipients with pre-transplant malignancies. *J Heart Lung Transplant.* Dec 2012;31(12):1276-1280. PMID 23089300
19. Yoosabai A, Mehta A, Kang W, et al. Pretransplant malignancy as a risk factor for posttransplant malignancy after heart transplantation. *Transplantation.* Feb 2015;99(2):345-350. PMID 25606783
20. Agüero F, Castel MA, Cocchi S, et al. An update on heart transplantation in human immunodeficiency virus-infected patients. *Am J Transplant.* Jan 2016;16(1):21-28. PMID 26523614
21. Working Party of the British Transplantation Society. *Kidney and Pancreas Transplantation in Patients with HIV. Second Edition (Revised). British Transplantation Society Guidelines.* Macclesfield, UK: British Transplantation Society; 2017.
22. Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. *J Heart Lung Transplant.* Jan 2015;34(1):1-15. PMID 25085497
23. Center for Medicare & Medicaid Services (CMS). Decision Memo for TRANSPLANT Centers: Re-Evaluation of Criteria for Medicare Approval (CAG-00061N). 2000; https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=75&NcaName=Transplant+Centers*3a%24+Re-Evaluation+of+Criteria+for+Medicare+Approval&CoverageSelection=National&Keyword=transplant&KeywordLookUp=Title&KeywordSearchType=And&bc=gAAAABAAEAAA&. Accessed July 16, 2018.